Literature DB >> 4022359

Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions.

G R Uhl, J C Hedreen, D L Price.   

Abstract

Decreased numbers of pigmented neurons of the dopaminergic nigrostriatal system are the most striking pathology in the brains of individuals with Parkinson's disease (PD), but it is clear that neurons in the locus ceruleus, vagal nuclei, and nucleus basalis of Meynert are also affected in this disease. Because neurochemical evidence suggested that the mesolimbic dopaminergic system originating in the ventral tegmental area (VTA) may also be involved, the present study was designed to evaluate the mesolimbic dopamine system in PD by counting pigmented neurons in the VTA contralateral to therapeutic lesions placed in the basal ganglia or thalamus. In PD, VTA neurons were depleted to 36 to 55% of control values. Moreover, the VTA showed excessive free pigment, a marker for death of pigmented neurons. These changes may be important in disorders of movement or mentation occurring in PD.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4022359     DOI: 10.1212/wnl.35.8.1215

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

1.  Implicit motor sequence learning is not purely perceptual.

Authors:  D B Willingham
Journal:  Mem Cognit       Date:  1999-05

2.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Molecular basis for catecholaminergic neuron diversity.

Authors:  Jan Grimm; Anne Mueller; Franz Hefti; Arnon Rosenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-07       Impact factor: 11.205

4.  Chronic restraint stress triggers dopaminergic and noradrenergic neurodegeneration: Possible role of chronic stress in the onset of Parkinson's disease.

Authors:  Shuei Sugama; Kazunari Sekiyama; Tohru Kodama; Yoshiki Takamatsu; Takato Takenouchi; Makoto Hashimoto; Conti Bruno; Yoshihiko Kakinuma
Journal:  Brain Behav Immun       Date:  2015-08-17       Impact factor: 7.217

Review 5.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 6.  Rule-based category learning in patients with Parkinson's disease.

Authors:  Amanda Price; J Vincent Filoteo; W Todd Maddox
Journal:  Neuropsychologia       Date:  2009-02-02       Impact factor: 3.139

Review 7.  Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy.

Authors:  Alexander M Lopez; Daniel Weintraub; Daniel O Claassen
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Authors:  R Cantello; M Aguggia; M Gilli; M Delsedime; I Chiardò Cutin; A Riccio; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

10.  Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.

Authors:  T J Counihan; J B Penney
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.